aibioArmata Pharmaceuticals enters $15 million secured term loan with Innoviva at 14.0% interest
Tickers ARMP
A $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025.
Key facts
- Company
- Armata Pharmaceuticals, Inc. (AMEX: ARMP)
- News type
- Debt Financing
- Primary source
- Armata Pharmaceuticals, Inc. Form 8-K filed August 12, 2025 (SEC EDGAR)
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) entered into a $15 million secured term loan on August 11, 2025 with Innoviva Strategic Opportunities LLC, according to a Form 8-K filed August 12, 2025. The loan carries an interest rate of 14.0% per year and matures on January 11, 2029. The filing says the lender is a wholly owned subsidiary of Innoviva, Inc., which it calls a principal shareholder of Armata.
The terms of the loan
Armata is the borrower under the August 2025 Credit Agreement. Its domestic subsidiaries guarantee repayment, and the loan is secured by substantially all of the assets of Armata and those guarantors. The agreement's exhibit lists the lender's commitment as $15,000,000. Innoviva Strategic Opportunities LLC is the only lender named. The 8-K and the agreement name no placement agent, financial advisor or counsel for the loan.
The agreement contains customary affirmative and negative covenants, along with representations and warranties. The negative covenants limit indebtedness, liens, distributions including dividends, and mergers or acquisitions. The events of default include payment defaults, breaches of the loan documents, bankruptcy or insolvency events, events that could reasonably be expected to have a material adverse effect, and a material deviation from Armata's operating budget.
A lender that is also a shareholder
The release describes Innoviva, Inc. as Armata's largest shareholder. The filing uses the term principal shareholder.
In the release, Chief Executive Officer Dr. Deborah Birx, discussing the AP-SA02 program, said: "We are very grateful for the ongoing support of Innoviva and the U.S. Department of Defense for providing critical funding to enable us to continue to advance this promising program."
Trial claims and what the release leaves out
The release says proceeds will be used to continue developing AP-SA02, an intravenous multi-phage therapeutic that Armata is studying for complicated S. aureus bacteremia. It reports positive topline results from the Phase 1b/2a diSArm trial, announced May 19, 2025. The release says the study met all primary endpoints for safety, tolerability and clinical response in the intent-to-treat population, and that the AP-SA02 arm significantly improved clinical outcomes compared with the best available antibiotic therapy. Birx called the data the first clear evidence in a randomized controlled trial of the effectiveness of phage in treating a serious systemic bacterial infection.
The release does not give the number of patients in the diSArm trial or the size of each arm.
Cash and debt
The release says Armata held approximately $4.3 million of unrestricted cash and cash equivalents on June 30, 2025, compared with $9.3 million on December 31, 2024. Its condensed balance sheet shows current assets of $7,520 thousand and current liabilities of $120,085 thousand at that date. Term debt within current liabilities is $78,891 thousand, against $38,954 thousand at December 31, 2024. The net loss for the six months ended June 30, 2025 was $22,826 thousand.
The balance sheet also carries a current convertible loan of $33,445 thousand, none of which was current at December 31, 2024. The release also reports an additional $4.65 million of non-dilutive funding under a previously announced Department of Defense award managed through the Medical Technology Enterprise Consortium.
Going concern and what comes next
The 2024 annual report says there is substantial doubt about its ability to continue as a going concern. The report says that doubt may affect its ability to obtain future financing and may require it to curtail operations. It adds that the company will need substantial additional financing to develop its product candidates, including to support one or more pivotal trials in 2025 and beyond.
The release says Armata plans an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in the second half of 2025 to align on a superiority trial design. It also says the company intends to begin enrolling patients in a Phase 3 pivotal trial in 2026. The new loan adds a 14.0% obligation to that balance sheet. The release does not say how the company plans to repay its current term debt.